Creso Pharma


Khiron Life Sciences Corp.

CVE: KHRN


Canadian symbol: KHRN.V
US symbol: KHRNF

Currency in CAD

Valuation Measures

Market Cap (intraday) 585.6M
Enterprise Value 373.79M
Trailing P/E N/A
Forward P/E 1-4.75
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)10.69
Price/Book (mrq)1.31
Enterprise Value/Revenue 39.21
Enterprise Value/EBITDA 7-2.37

Trading Information

Stock Price History

Beta (5Y Monthly) 2.10
52-Week Change 39.62%
S&P500 52-Week Change 349.51%
52 Week High 30.9000
52 Week Low 30.3250
50-Day Moving Average 30.5750
200-Day Moving Average 30.4592

Share Statistics

Avg Vol (3 month) 3903.96k
Avg Vol (10 day) 3319.47k
Shares Outstanding 5150.17M
Implied Shares Outstanding 6N/A
Float 133.54M
% Held by Insiders 111.22%
% Held by Institutions 12.22%
Shares Short (Mar. 30, 2021) 4272.5k
Short Ratio (Mar. 30, 2021) 40.26
Short % of Float (Mar. 30, 2021) 4N/A
Short % of Shares Outstanding (Mar. 30, 2021) 40.18%
Shares Short (prior month Feb. 25, 2021) 4305.78k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3May 23, 2018
Ex-Dividend Date 4N/A
Last Split Factor 21:8
Last Split Date 3May 23, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Sep. 29, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-388.74%

Management Effectiveness

Return on Assets (ttm)-25.05%
Return on Equity (ttm)-44.71%

Income Statement

Revenue (ttm)8.01M
Revenue Per Share (ttm)0.07
Quarterly Revenue Growth (yoy)-30.50%
Gross Profit (ttm)2.44M
EBITDA -31.09M
Net Income Avi to Common (ttm)-29.9M
Diluted EPS (ttm)-0.2630
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)14.62M
Total Cash Per Share (mrq)0.1
Total Debt (mrq)2.82M
Total Debt/Equity (mrq)5.51
Current Ratio (mrq)3.49
Book Value Per Share (mrq)0.43

Cash Flow Statement

Operating Cash Flow (ttm)-27.29M
Levered Free Cash Flow (ttm)-21.53M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
4 months ago
KHRN.V
Khiron Life Sciences
4 months ago
KHRN.V
Khiron Life Sciences
4 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
6 months ago
KHRN.V
Khiron Life Sciences
6 months ago
KHRN.V
Khiron Life Sciences
6 months ago
KHRN.V
Khiron Life Sciences
7 months ago
KHRN.V
Khiron Life Sciences
7 months ago
KHRN.V
Khiron Life Sciences
7 months ago
KHRN.V
Khiron Life Sciences
7 months ago
KHRN.V
Khiron Life Sciences
7 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts0011
Avg. Estimate00-0.24-0.12
Low Estimate00-0.24-0.12
High Estimate00-0.24-0.12
Year Ago EPS-0.11-0.09-0.36-0.24
Revenue EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts1111
Avg. Estimate1.9M2.8M7.6M34M
Low Estimate1.9M2.8M7.6M34M
High Estimate1.9M2.8M7.6M34M
Year Ago Sales2.21M2.77M9.58M7.6M
Sales Growth (year/est)-13.90%1.00%-20.70%347.40%
Earnings History2019-06-292019-09-292019-12-302020-03-30
EPS Est.-0.09-0.08-0.09-0.09
EPS Actual-0.11-0.09-0.06-0.08
Difference-0.02-0.010.030.01
Surprise %-22.20%-12.50%33.30%11.10%
EPS TrendCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Current Estimate00-0.24-0.12
7 Days Ago-0.07-0.05-0.24-0.12
30 Days Ago-0.07-0.05-0.24-0.12
60 Days Ago-0.07-0.05-0.24-0.12
90 Days Ago-0.07-0.05-0.24-0.12
EPS RevisionsCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Up Last 7 DaysN/A1N/AN/A
Up Last 30 DaysN/A1N/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesKHRN.VIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current Year33.30%N/AN/AN/A
Next Year50.00%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
11.22%% of Shares Held by All Insider
2.22%% of Shares Held by Institutions
2.50%% of Float Held by Institutions
6Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
AdvisorShares Investments, LLC778,257Dec. 30, 20200.52%291,846

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
AdvisorShares Trust-AdvisorShares Pure Cannabis ETF850,921Mar. 30, 20210.56%476,515
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Khiron Life Sciences Corp.


Khiron Expands Product Offering in UK and Increases Patient Access

Khiron Expands Product Offering in UK and Increases Patient Access

Following successful medical cannabis launch in Germany, Khiron 1/14, a high CBD flower is expected to be available in Q2/21 for UK patients Khiron plans to introduce additional cannabis-based medical products with its registered strains, recently exported from Colombia to Europe Supply chain improvements will increase availability of ... Read More...
Khiron Medical Cannabis Products Arrive in Germany for Immediate Prescription, Sale and Distribution

Khiron Medical Cannabis Products Arrive in Germany for Immediate Prescription, Sale and Distribution

First shipment of Khiron branded EU-GMP certified medical cannabis to Germany successfully completed, providing immediate access to German market through distribution partner, Nimbus Health GmbH Launch product is Khiron 1/14 high-CBD flower, which will focus on indications such as anxiety, substance use disorder, and migraines, addressi... Read More...
Khiron Updates Zerenia™ Expansion Program; Announces Plans to Open Three Additional Satellite Clinics in Colombia by End of Q2

Khiron Updates Zerenia™ Expansion Program; Announces Plans to Open Three Additional Satellite Clinics in Colombia by End of Q2

"We are off to a great start in 2021 and the Zerenia satellite clinic model is proving to be an exceptional platform for reaching new patients. The rapid expansion of clinics is helping Khiron reach more patients in more places, more conveniently, in these cities. With the opening of two new satellite clinics in Cali and Bucaramanga, Khir... Read More...
Khiron Becomes First Colombian Medical Cannabis Company to Export Live Cannabis Clones to Europe

Khiron Becomes First Colombian Medical Cannabis Company to Export Live Cannabis Clones to Europe

Tejinder Virk, President of Khiron Europe, commented: "Our experience in Colombia and Europe tells us that doctors require solid clinical evidence to feel confident that medical cannabis is the right treatment for their patients. By exporting our Colombian cannabis strains, we will be able to bring our Latin American extracts to European ... Read More...
Khiron and Tecnologico de Monterrey of Mexico Launch First Internationally Accredited Medical Cannabis Diploma in Latin America

Khiron and Tecnologico de Monterrey of Mexico Launch First Internationally Accredited Medical Cannabis Diploma in Latin America

International Diploma in Medicinal Cannabis for Latin American doctors to be hosted virtually through Mexico's TecSalud School of Medicine and Health Sciences (EMCS), beginning February 20, 2021 Physicians from Mexico and across Latin America will participate in a fee-based 6-week diploma program Diploma marks a historic advance in med... Read More...
Khiron Announces Expansion of Small-Format Zerenia™ Clinics in Colombia Following Success of Initial Launch

Khiron Announces Expansion of Small-Format Zerenia™ Clinics in Colombia Following Success of Initial Launch

Khiron to launch two additional small-format Zerenia™ clinics in major metropolitan centres outside of Bogota in early March 2021, following successful launch of the Company's first small-format clinic in Medellin in December 2020 New clinics bring Khiron's total number of clinics in Colombia to six, expanding regional access throughout... Read More...
Khiron CEO to Participate at ATB 9th Annual Institutional Investor Conference

Khiron CEO to Participate at ATB 9th Annual Institutional Investor Conference

TORONTO, Jan. 8, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and director, will participate live at the ATB 9th Annual Institutional Investor Conf... Read More...
article placeholder

Khiron to Present at the 13th Annual LD Micro Main Event Conference

TORONTO, Dec. 11, 2020 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announced that it will be presenting at the 13th Annual LD Micro Main Event investor conference on December 14th. Khiron Chairman ... Read More...
Khiron Becomes First Company to Export High THC Medical Cannabis From Colombia

Khiron Becomes First Company to Export High THC Medical Cannabis From Colombia

Khiron High THC medical cannabis product successfully imported into Peru, with first prescriptions to be filled in December through a partnership with Farmacia Universal S.A.C. Khiron is the first company to export High THC medical cannabis from Colombia, and the only Colombian company authorized to fill High THC prescriptions in Peru f... Read More...
Khiron Life Sciences Corp Invites You to Join Us at the Benzinga Global Small Cap Conference

Khiron Life Sciences Corp Invites You to Join Us at the Benzinga Global Small Cap Conference

Toronto, Ontario--(Newsfile Corp. - December 7, 2020) - Khiron Life Sciences Corp (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America and Europe, will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2020. We invite our shareholders and all inter... Read More...
Khiron Medical Cannabis Products Now Qualify for National Insurance Coverage in Colombia

Khiron Medical Cannabis Products Now Qualify for National Insurance Coverage in Colombia

Khiron applauds Colombia on becoming one of the first countries to extend national health insurance for patients to include medical cannabis as a first line therapy Leveraging Khiron's status as a National Strategic Project, Khiron medical cannabis products and clinic services are now covered by health insurance companies in Colombia O... Read More...
Khiron to Open New Regional Zerenia™ Clinic in Medellin, Colombia

Khiron to Open New Regional Zerenia™ Clinic in Medellin, Colombia

The Medellin clinic, with a grand opening planned for December 8, 2020, supports Khiron´s goal of expanding regional access to the Company's proven clinic services and medical cannabis products for patients across the country, with a focus on in-person and telehealth services in Colombia's largest urban centres. The clinic is convenientl... Read More...
Juan Carlos Echeverry, Former Colombian Minister of Finance and Former CEO of Colombia's Largest Company, Joins Khiron Board of Directors

Juan Carlos Echeverry, Former Colombian Minister of Finance and Former CEO of Colombia’s Largest Company, Joins Khiron Board of Directors

Distinguished economist and former CEO of Ecopetrol, Colombia's largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500 Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy Adds proven economic and international business experi... Read More...
Khiron Plans to Launch Its Zerenia™ Medical Cannabis Clinic Strategy in Mexico; Applauds Mexican Senate Approval of Legislation for Cannabis in Mexico

Khiron Plans to Launch Its Zerenia™ Medical Cannabis Clinic Strategy in Mexico; Applauds Mexican Senate Approval of Legislation for Cannabis in Mexico

On November 19, the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally On March 31, 2020, the Company entered into an agreement with Tecnologico de Monterrey, the leading university in Mexico, to educate physicians across Latin Amer... Read More...
Khiron Life Sciences Announces Closing of $14.49 Million Bought Deal Financing Including Full Exercise of Over-Allotment Option

Khiron Life Sciences Announces Closing of $14.49 Million Bought Deal Financing Including Full Exercise of Over-Allotment Option

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESTORONTO, Nov. 26, 2020 -- Khiron Life Sciences Corp. (“Khiron” or, the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that it ha... Read More...
Khiron Life Sciences Re-Files Q2 2020 Interim Financial Statements to Correct Comparative Disclosure and Certain Presentation

Khiron Life Sciences Re-Files Q2 2020 Interim Financial Statements to Correct Comparative Disclosure and Certain Presentation

TORONTO, Nov. 23, 2020 -- Khiron Life Sciences Corp. (“Khiron” or, the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “Interi... Read More...
Khiron Life Sciences Announces Upsize of Previously Announced Bought Deal Financing to $12.6 Million

Khiron Life Sciences Announces Upsize of Previously Announced Bought Deal Financing to $12.6 Million

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/TORONTO, Nov. 9, 2020 - Khiron Life Sciences Corp. ("Khiron" or, the "Company") (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that it has ... Read More...
Khiron Life Sciences enters into $10 million bought deal financing

Khiron Life Sciences enters into $10 million bought deal financing

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ TORONTO, Nov. 9, 2020 - Khiron Life Sciences Corp. ("Khiron" or, the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced today that it has ente... Read More...
Khiron Appoints Joel Friedman to Succeed Wendy Kaufman as Chief Financial Officer

Khiron Appoints Joel Friedman to Succeed Wendy Kaufman as Chief Financial Officer

TORONTO, Oct. 19, 2020 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a medical cannabis leader with core operations in Latin America and Europe announced the appointment, effective October 16, of Joel Friedman as CFO following the resignation of Wendy Kaufman, the Company's CFO since July, 2019... Read More...
Khiron CEO to Present at Benzinga Virtual Cannabis Capital Conference

Khiron CEO to Present at Benzinga Virtual Cannabis Capital Conference

TORONTO, Oct. 14, 2020 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and director, will present live at the Benzinga Virtual Cannabis Capital Conferenc... Read More...
Khiron To Present at Canaccord Genuity Virtual US Cannabis Symposium on September 30th

Khiron To Present at Canaccord Genuity Virtual US Cannabis Symposium on September 30th

TORONTO, Sept. 28, 2020 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and Director, and Chris Naprawa, Khiron Chairman, will present live at Canaccord ... Read More...
Khiron Becomes First Company to Sell Medical Cannabis in Peru, and Surpasses 3,000 Prescriptions in Colombia

Khiron Becomes First Company to Sell Medical Cannabis in Peru, and Surpasses 3,000 Prescriptions in Colombia

First prescriptions for Khiron's medical cannabis in Peru are filled as the Company surpasses 3,000 medical cannabis prescription milestone in Colombia Khiron becomes the first Company to sell and fill medical cannabis prescriptions through private pharmacies in Peru The Company began sales in Peru with full spectrum High CBD supplied ... Read More...
Khiron Declared a National Strategic Project by the Government of Colombia

Khiron Declared a National Strategic Project by the Government of Colombia

Status Accelerates Ability to Bring New Products and Services to Market The National Interest Strategic Project certification ("PINES") was established by the Government of Colombia to prioritize the development of specific projects or companies that are deemed by the Government to be able to significantly increase the national economy ... Read More...
Khiron Announces Shareholder Approval of Amended and Restated Option Plan and Restricted Share Unit Plan, and Grants of RSUs

Khiron Announces Shareholder Approval of Amended and Restated Option Plan and Restricted Share Unit Plan, and Grants of RSUs

TORONTO, Sept. 11, 2020 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the adoption of the Company's amended and restated stock option plan and the Company's amended and restated restricted share ... Read More...
Khiron Enters Exclusive Partnership with RAPPI, Latin America's Largest Home Multi-Vertical App Platform

Khiron Enters Exclusive Partnership with RAPPI, Latin America’s Largest Home Multi-Vertical App Platform

Rappi is the largest home multi-Vertical app in Latin America, which received a USD 1 Billion investment from Softbank Group Corp. and Softbank Vision Fund, reaching unicorn status in 2019. Rappi operates in Brazil, Colombia, Mexico, Argentina, Chile, Costa Rica, Uruguay, Ecuador and Peru, which together represent a population of over 60... Read More...
Khiron Announces Change of Auditor

Khiron Announces Change of Auditor

TORONTO, July 21, 2020 -- Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), announces that MNP LLP (the “Former Auditor”) have, at the request of the Company, resigned as auditors of the Company, effective July 10, 2020. Accordingly, the Board of Directors has appointed BDO Canada LL... Read More...
Khiron Signs Distribution Deal in Germany for Medical Cannabis Imports and Sales

Khiron Signs Distribution Deal in Germany for Medical Cannabis Imports and Sales

Khiron partners with Nimbus Health, a leading medical cannabis distributor in Germany, with broad reach into domestic pharmacies First import and sales of Khiron branded EU GMP medical cannabis products are expected in Q3/20 Medical education and marketing activities to begin imminently Germany is the largest medical cannabis market i... Read More...
Khiron Goes Green, Completing 1 Megawatt Solar Energy Park in Colombia

Khiron Goes Green, Completing 1 Megawatt Solar Energy Park in Colombia

Developed with ReFeel, a leading Italian renewable Company with more than 80 MW installed in Europe and Latin America, Khiron's solar park is expected to generate up to 700 kWh through a photovoltaic (PV) system that comprises 2,618 installed solar panels. With the construction of the PV system, Khiron can self-generate up to 40% of the ... Read More...
Khiron Appoints Chris Naprawa to Director, and Chairman of the Board

Khiron Appoints Chris Naprawa to Director, and Chairman of the Board

TORONTO, June 12, 2020 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces today the appointment of Chris Naprawa as Director and  Chairman of the Board. In transitioning from his curr... Read More...
Khiron Life Sciences Reports First Quarter Fiscal 2020 Financial Results

Khiron Life Sciences Reports First Quarter Fiscal 2020 Financial Results

Closed quarter with net working capital of $28.4 million Achieved revenues of $1.9 Million for Q1 2020, improving gross margin by 17% compared to Q1 2019 Achieved first sales in Colombia of low-THC medical cannabis, and subsequent to the quarter, began its first high-THC medical cannabis sales in Colombia on May 19th 2020 Increased re... Read More...
Khiron Receives First Medical Cannabis Prescriptions for UK Patients Participating in Project Twenty21

Khiron Receives First Medical Cannabis Prescriptions for UK Patients Participating in Project Twenty21

Khiron is the exclusive Latin American supplier to Project Twenty21, a leading UK registry study enrolling up to 20,000 patients by the end of 2021, to create the largest body of evidence in Europe for the effectiveness and tolerability of medical cannabis First import of EU GMP medical cannabis products is complete Khiron branded produc... Read More...
Khiron Life Sciences Reports 2019 Fiscal Year End Results and Provides Corporate Update

Khiron Life Sciences Reports 2019 Fiscal Year End Results and Provides Corporate Update

Net working capital of $36.4 Million CAD at December 31, 2019 On March 20, 2020 Khiron became the first and only company in Colombia to receive full authorization to manufacture high- and low-THC medical cannabis, and to fill prescriptions for low-THC medical cannabis Khiron became the only Company authorized to export THC products Fi... Read More...
Khiron Signs Exclusive Agreement with Medlive, a Distributor Serving 3,000 Clinics and Hospitals in Brazil

Khiron Signs Exclusive Agreement with Medlive, a Distributor Serving 3,000 Clinics and Hospitals in Brazil

Exclusive agreement with Medlive, a pharmaceutical and health products distributor with network of over 3,000 clinics and hospitals in southern Brazil Company's medical cannabis products will be marketed through Medlive network of doctor offices, clinics, hospitals and governmental institutions Medical education, marketing activities a... Read More...
Khiron Provides Update on Filing of its 2019 Year End Results

Khiron Provides Update on Filing of its 2019 Year End Results

Company filing date moved from April 29 to estimate of May 1 to allow auditors to complete audit delayed as a result of COVID-19 situation  Filing extension provided by Ontario Securities Commission on March 23, 2020 in response to COVID-19 pandemic TORONTO, April 28, 2020 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
KHRN.V
TSX Venture Exchange (former Canadian Ventures Exchange)
TSX Venture Exchange (former Canadian Ventures Exchange)0.57CAD+1.79%
4KH.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange0.37EUR0.00%
KHRN.CCP
Canadian Composite Quote/Trade
Canadian Composite Quote/Trade0.57CAD+1.79%
KHRNF.PK
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.45USD-0.92%
4KH.BE
Berlin Stock Exchange
Berlin Stock Exchange0.38EUR-1.82%
4KH.SG
Stuttgart Stock Exchange
Stuttgart Stock Exchange0.37EUR0.00%
4KH.D
Dusseldorf Stock Exchange
Dusseldorf Stock Exchange0.37EUR-0.67%
4KH.H
Hamburg Stock Exchange
Hamburg Stock Exchange0.37EUR0.00%
4KH.MU
Munich Stock Exchange
Munich Stock Exchange0.38EUR0.00%
KHRN.GO
Canadian Securities Exchange/PURE - CSE Listed & Other Canadian Listed Securities
Canadian Securities Exchange/PURE - CSE Listed & Other Canadian Listed Securities0.56CAD-1.75%

Delayed data (1h)
NameAgePositionAppointed
Chris Naprawa
Chairman of the Board
49Chairman of the Board2020
Alvaro Torres
Chief Executive Officer, Director
40Chief Executive Officer, Director2018
Joel Friedman
Chief Financial Officer
--Chief Financial Officer2020
Juan Diego Alvarez
Vice President of Regulations
--Vice President of Regulations--
Matt Murphy
Vice President of Compliance
57Vice President of Compliance--
Andres Galofre
Vice President - Business Development
37Vice President - Business Development--
Maria Fernanda Aboleda
Medical Director
33Medical Director--
Juan Carlos Carlos Echeverry Garzon
Director
58Director2020
Vicente Fox Quesada
Director, Strategic Advisor and Brand Ambassador
76Director, Strategic Advisor and Brand Ambassador2018
Deborah E. Rosati
Independent Director
57Independent Director2019
Peter Simeon
Independent Director
42Independent Director2018
Alvaro Yanez
Independent Director
41Independent Director2018


Share this page